Perigon Wealth Management’s ANI Pharmaceuticals ANIP Stock Holding History

Perigon Wealth Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3	Closed	–	–	252
2018 Q1	$0	Buy	+3	New	+$190	﹤0.01%	635

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Perigon Wealth Management's ANIP Position: Q2 2018 in Review

Perigon Wealth Management sold out of ANI Pharmaceuticals (ANIP) in Q2 2018, closing a stake of 3 shares.

Perigon Wealth Management first reported a position in ANIP in Q1 2018 and held it in 1 quarter. The position peaked at $0 in Q1 2018. 184 funds tracked by Wall St. Rank hold ANIP as of Q2 2018.

Perigon Wealth Management reported no remaining ANI Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Perigon Wealth Management sold 3 ANI Pharmaceuticals shares in Q2 2018.
Perigon Wealth Management first reported a position in ANI Pharmaceuticals in Q1 2018 and held it in 1 quarter.
Perigon Wealth Management's ANI Pharmaceuticals position peaked at $0 in Q1 2018.
184 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2018.

Based on Perigon Wealth Management's 13F filing for Q2 2018, filed 7 Aug 2018.